Published 2 months ago

Gilead CAR-T cancer therapy capacity to quadruple by 2026

Summary by Ground News

Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026. Gilead paid nearly $12 billion in 2017 to buy Kite, one of the leading players in the emerging field of CAR-T therapies. The company has been working for several years to build its presence in oncology.

0 Articles

All

Left

Center

Right

WTVB

Gilead CAR-T cancer therapy capacity to quadruple by 2026

By Michael Erman FREDERICK, Maryland (Reuters) – Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech’s manufacturing processes, an executive in charge of that business told Reuters. Cindy Perettie, executive vice president of Gilead’s Kite cell therapy unit, said these changes have already allowed the company to increase the number of patient treatments it…

2 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.